Gismo Therapeutics
PrivateLast Round
Grant
Aug 25, 2023
Total Funding Raised
$4.55M
Company Overview
Gismo Therapeutics operates in Healthcare & Life Sciences and is based in Lexington, Kentucky. Its latest recorded funding round was a Grant round in August 2023.
Gismo Therapeutics is a biotechnology company developing first-in-class, disease-modifying oral therapeutics for the treatment of Alzheimer's and Parkinson's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gismo Therapeutics Comparables
Compare Gismo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Treventis Corporation | 83% | |
| Oligomerix, Inc. | 81% | |
| WaveBreak Therapeutics | 79% |
For institutional investors. Book with your work email.
Gismo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 25, 2023 | ||||
| Grant | Jun 16, 2022 | ||||
| Grant | Jun 14, 2019 | ||||
| Grant | Oct 12, 2017 | ||||
| Grant | Dec 3, 2014 |
For institutional investors. Book with your work email.
Gismo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | Grant |
| National Institute on Aging | Grant |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| U.S. Department of War | Grant |
| Kentucky Cabinet for Economic Development | Grant |
| Congressionally Directed Medical Research Programs | Grant |
| National Institutes of Health (NIH) | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 21, 2026
Monthly visitors increased 46% MoM, reaching 1K.
- Oct 30, 2024
Monthly visitors grew 34% MoM, reaching 1K.
For institutional investors. Book with your work email.
Gismo Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Gismo Therapeutics's valuation, stock price, and market status.
Is Gismo Therapeutics a public or private company?
Gismo Therapeutics is a private company.
What is the current stock price of Gismo Therapeutics?
Gismo Therapeutics is a private company, so its shares have no public market price. Caplight tracks Gismo Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Gismo Therapeutics worth (valuation)?
Valuation information for Gismo Therapeutics is not publicly available.
Can I buy Gismo Therapeutics stock?
Gismo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Gismo Therapeutics's last funding round?
Gismo Therapeutics's most recent funding round was Grant on August 25, 2023.
Who are the main investors in Gismo Therapeutics?
Key investors in Gismo Therapeutics include National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging, The Michael J. Fox Foundation for Parkinson's Research, U.S. Department of War, Kentucky Cabinet for Economic Development.
Will Gismo Therapeutics IPO soon?
No public IPO plans have been announced for Gismo Therapeutics.
How can I track Gismo Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Gismo Therapeutics's shares on secondary markets.